➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Merck
Boehringer Ingelheim
Express Scripts
AstraZeneca

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

TIVORBEX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Tivorbex patents expire, and when can generic versions of Tivorbex launch?

Tivorbex is a drug marketed by Genus and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-seven patent family members in twenty-one countries.

The generic ingredient in TIVORBEX is indomethacin. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the indomethacin profile page.

US ANDA Litigation and Generic Entry Outlook for Tivorbex

A generic version of TIVORBEX was approved as indomethacin by SANDOZ on April 29th, 1987.

  Start Trial

US Patents and Regulatory Information for TIVORBEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-001 Feb 24, 2014 RX Yes No   Start Trial   Start Trial   Start Trial
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-002 Feb 24, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-001 Feb 24, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-001 Feb 24, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-002 Feb 24, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Genus TIVORBEX indomethacin CAPSULE;ORAL 204768-002 Feb 24, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Johnson and Johnson
Harvard Business School
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.